Skip to main content

Peer Review reports

From: Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)

Original Submission
22 Apr 2022 Submitted Original manuscript
13 May 2022 Author responded Author comments - Bernard Jan Smilde
Resubmission - Version 2
13 May 2022 Submitted Manuscript version 2
24 May 2022 Editorially accepted
1 Jun 2022 Article published 10.1186/s12891-022-05471-x

You can find further information about peer review here.

Back to article page